These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 19596967)

  • 21. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
    Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
    Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Splenectomy and surgical cytoreduction for ovarian cancer.
    Chen LM; Leuchter RS; Lagasse LD; Karlan BY
    Gynecol Oncol; 2000 Jun; 77(3):362-8. PubMed ID: 10831343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma].
    Zang R; Zhang Z; Cai S
    Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
    Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
    Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?
    Zang RY; Li ZT; Tang J; Cheng X; Cai SM; Zhang ZY; Teng NN
    Cancer; 2004 Mar; 100(6):1152-61. PubMed ID: 15022281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
    Chi DS; Venkatraman ES; Masson V; Hoskins WJ
    Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Scarabelli C; Gallo A; Carbone A
    Gynecol Oncol; 2001 Dec; 83(3):504-12. PubMed ID: 11733963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
    Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
    Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
    Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical significance of secondary cytoreductive surgery for recurrent advanced ovarian cancer].
    Zang R; Zhang Z; Cai S
    Zhonghua Zhong Liu Za Zhi; 2002 Mar; 24(2):194-6. PubMed ID: 12015048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.
    Munkarah AR; Coleman RL
    Gynecol Oncol; 2004 Nov; 95(2):273-80. PubMed ID: 15491746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary cytoreduction in epithelial ovarian cancer recurrence: a perspective from a regional cancer center in India.
    Rema PN; Suchetha S; Mathew AP; Mathew A; Sebastian P
    J Reprod Med; 2009 Aug; 54(8):506-10. PubMed ID: 19769197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer.
    Park JY; Eom JM; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
    J Surg Oncol; 2010 Apr; 101(5):418-24. PubMed ID: 20082350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.
    Kolwijck E; Span PN; Thomas CM; Bulten J; Sweep FC; Massuger LF
    Oncol Rep; 2010 Feb; 23(2):579-84. PubMed ID: 20043124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of Ca 125 levels during primary therapy.
    Markmann S; Gerber B; Briese V
    Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Shih KK; Chi DS; Barakat RR; Leitao MM
    Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinicopathological features and prognosis of 68 patients with metastatic ovarian tumors from the gastric cancer].
    Zhao JZ; Wang G; Zhang RP; Liang H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Feb; 13(2):129-32. PubMed ID: 20186624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.
    Lukácskó I; Hernádi Z; Sápy T; Borsos A
    Acta Chir Hung; 1997; 36(1-4):213-4. PubMed ID: 9408350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.
    Pavlov MJ; Kovacevic PA; Ceranic MS; Stamenkovic AB; Ivanovic AM; Kecmanovic DM
    Eur J Surg Oncol; 2009 Nov; 35(11):1186-91. PubMed ID: 19356887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.